1.

Record Nr.

UNINA9910815052503321

Titolo

Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others]

Pubbl/distr/stampa

Hoboken, New Jersey : , : Wiley, , 2014

©2014

ISBN

1-118-77816-2

1-118-77815-4

Descrizione fisica

1 online resource (760 p.)

Collana

Wiley Series on Technologies for the Pharmaceutical Industry

Disciplina

615.1/9

Soggetti

Drug Discovery

Public-Private Sector Partnerships

Drug development

Public-private sector cooperation

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references at the end of each chapters and index.

Nota di contenuto

Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry

2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People



Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References

4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery

Future Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References

6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with Academia

New Initiatives to Transform University-Industry Collaborations

Sommario/riassunto

Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving d